

# ARCUS OVERVIEW

NYSE: RCUS

ARCUS  
BIOSCIENCES

Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer

## HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



**Targets:** CD73, HIF2α, A2a/2b, AXL



**Targets:** TIGIT, PD-1, CD39

**Goal of 1-2**  
new molecules advancing  
into clinic each year



**Accelerated**  
P 1/2 signal-  
seeking &  
platform studies

## DIVERSE PIPELINE WITH MULTIPLE “SHOTS ON GOAL”

**7**



Different  
molecules  
in clinic

**3**



Registrational Phase  
3 trials evaluating a  
differentiated, Fc-silent  
anti-TIGIT antibody  
domvanalimab

**24-36**



Months for  
potential approval  
& revenue  
generation

**\$10B+**



Addressable market  
opportunity in the U.S.  
based on expected  
drug treatable patient  
population

## TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

**~\$1.7B**

- Holds ~33% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.



## STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING INTO 2027



**~\$1.1B**

cash, cash equivalent  
& marketable securities as of 3/31/2024

## HQ & RESEARCH CAMPUSES IN BAY AREA



**~600**

employees

Learn more at [investors.arcusbio.com](https://investors.arcusbio.com)

This summary is provided as of 3/31/24. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding into 2027, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at [investors.arcusbio.com](https://investors.arcusbio.com).